

**Supplementary Table 1 - Demographic, clinical and genetic characteristics of the study cohort at baseline and at 2-years follow-up.**

<b>Characteristics</b>	<b>Baseline</b> (McNeill <i>et al.</i> , 2012)		
	<b>HC</b>	<b>Het GBA</b>	<b>GD</b>
N. subjects	30	30	30
Sex (F/M)	17/13	18/12	16/ 14
Mean age, years	63 (range 50-89)	64 (range 50-80)	61 (range 50-89)
Most frequent genotype	-	N370S (46 %)	N370S/L444P (37 %)
GD Treatment (ERT/SRT/none)	-	-	25/2/3
<b>2-years follow-up</b> (Beavan <i>et al.</i> , 2015)			
	<b>HC</b>	<b>Het GBA</b>	<b>GD</b>
N. subjects	26	28	30
Sex (F/M)	12/14	16/12	16/14
Mean age, years	61 (range 50-89)	63.6 (range 50-80)	61 (range 50-89)
Most frequent genotype	-	N370S (50%)	N370S/L444P (36.7%)
GD Treatment (ERT/SRT/none)	-	-	25/2/3

Data are presented as published in the previous papers.

[Beavan, M. *et al.* (2015) 'Evolution of Prodromal Clinical Markers of Parkinson Disease in a GBA Mutation-Positive Cohort', *JAMA Neurology*, 72(2), p. 201. doi: 10.1001/jamaneurol.2014.2950.

McNeill, A. *et al.* (2012) 'Hyposmia and Cognitive Impairment in Gaucher Disease Patients and Carriers', 27(4), pp. 526–532. doi: 10.1002/mds.24945.

Abbreviations: ERT Enzyme Replacement Therapy. SRT Substrate Reduction Therapy.